title: Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.
abstract: BACKGROUND
  Kaposi sarcoma (KS) is the most common AIDS-defining tumour in HIV-infected individuals in Africa. Kaposi sarcoma herpes virus (KSHV) infection precedes development of KS. KSHV co-infection may be associated with worse outcomes in HIV disease and elevated KSHV viral load may be an early marker for advanced HIV disease among untreated patients. We examined the prevalence of KSHV among adults initiating antiretroviral therapy (ART) and compared immunological, demographic and clinical factors between patients seropositive and seronegative for KSHV.
  
  
  RESULTS
  We analyzed cross-sectional data collected from 404 HIV-infected treatment-naïve adults initiating ART at the Themba Lethu Clinic, Johannesburg, South Africa between November 2008 and March 2009. Subjects were screened at ART initiation for antibodies to KSHV lytic K8.1 and latent Orf73 antigens. Seropositivity to KSHV was defined as positive to either lytic KSHV K8.1 or latent KSHV Orf73 antibodies. KSHV viremia was determined by quantitative PCR and CD3, 4 and 8 lymphocyte counts were determined with flow cytometry. Of the 404 participants, 193 (48%) tested positive for KSHV at ART initiation; with 76 (39%) reactive to lytic K8.1, 35 (18%) to latent Orf73 and 82 (42%) to both. One individual presented with clinical KS at ART initiation. The KSHV infected group was similar to those without KSHV in terms of age, race, gender, ethnicity, smoking and alcohol use. KSHV infected individuals presented with slightly higher median CD3 (817 vs. 726 cells/mm3) and CD4 (90 vs. 80 cells/mm3) counts than KSHV negative subjects. We found no associations between KSHV seropositivity and body mass index, tuberculosis status, WHO stage, HIV RNA levels, full blood count or liver function tests at initiation. Those with detectable KSHV viremia (n = 19), however, appeared to present with signs of more advanced HIV disease including anemia and WHO stage 3 or 4 defining conditions compared to those in whom the virus was undetectable.
  
  
  CONCLUSIONS
  We demonstrate a high prevalence of KSHV among HIV-infected adults initiating ART in a large urban public-sector HIV clinic. KSHV viremia but not KSHV seropositivity may be associated with markers of advanced HIV disease.
authors.affiliation: Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand (York Avenue), Johannesburg (2193), South Africa. mmaskew@witshealth.co.za.
authors.forename: Mhairi
authors.initials: M
authors.lastname: Maskew
authors.forename: A Patrick
authors.initials: AP
authors.lastname: Macphail
authors.forename: Denise
authors.initials: D
authors.lastname: Whitby
authors.forename: Matthias
authors.initials: M
authors.lastname: Egger
authors.forename: Carole L
authors.initials: CL
authors.lastname: Wallis
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Fox
references.citation: J Med Virol. 2005 Jan;75(1):93-100
references.pmid: 15543582
references.citation: Lancet Oncol. 2008 Jul;9(7):683-92
references.pmid: 18598933
references.citation: AIDS. 2000 Sep 29;14(14):2109-16
references.pmid: 11061651
references.citation: J Allergy Clin Immunol. 2002 Aug;110(2):189-98
references.pmid: 12170257
references.citation: J Viral Hepat. 2008 May;15(5):323-30
references.pmid: 18208497
references.citation: AIDS Res Ther. 2007 May 14;4:11
references.pmid: 17502001
references.citation: Virol J. 2010 Jul 06;7:147
references.pmid: 20604948
references.citation: BMC Infect Dis. 2008 Aug 18;8:111
references.pmid: 18706107
references.citation: J Infect Dis. 1995 Sep;172(3):648-55
references.pmid: 7658055
references.citation: J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41
references.pmid: 10430217
references.citation: J Int AIDS Soc. 2005 Aug 30;7(3):66
references.pmid: 19825131
references.citation: J Virol. 2002 Mar;76(6):2634-40
references.pmid: 11861829
references.citation: J Antimicrob Chemother. 2000 Apr;45 Suppl T3:15-27
references.pmid: 10855768
references.citation: Eur J Clin Microbiol Infect Dis. 2001 Apr;20(4):253-9
references.pmid: 11399015
references.citation: J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):383-92
references.pmid: 15097155
references.citation: Cancer. 2004 Jun 15;100(12):2644-54
references.pmid: 15197808
references.citation: HIV Med. 2005 May;6(3):198-205
references.pmid: 15876287
references.citation: J Infect Dis. 2004 Oct 15;190(8):1382-6
references.pmid: 15378429
references.citation: N Engl J Med. 2000 Nov 9;343(19):1369-77
references.pmid: 11070101
references.citation: Lancet. 1995 Sep 23;346(8978):799-802
references.pmid: 7674745
references.citation: Br J Cancer. 1998 Dec;78(11):1521-8
references.pmid: 9836488
references.citation: J Biomed Sci. 2009 Nov 18;16:102
references.pmid: 19922646
references.citation: AIDS. 2004 Jan 2;18(1):89-97
references.pmid: 15090834
references.citation: Intervirology. 2003;46(2):105-13
references.pmid: 12684549
references.citation: Int J Cancer. 2008 May 15;122(10):2260-5
references.pmid: 18241034
references.citation: AIDS. 2008 Feb 19;22(4):519-26
references.pmid: 18301065
references.citation: J Int Assoc Physicians AIDS Care (Chic). 2006 Sep;5(3):93-102
references.pmid: 16928877
references.citation: Eur J Cancer. 2001 Jul;37(10):1188-201
references.pmid: 11423251
references.citation: Science. 1998 Mar 27;279(5359):2103-6
references.pmid: 9516110
references.citation: Lancet. 2000 Apr 1;355(9210):1131-7
references.pmid: 10791375
references.citation: JAMA. 1998 Feb 11;279(6):450-4
references.pmid: 9466638
references.citation: J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5
references.pmid: 17195763
references.citation: BMJ. 1999 Jul 3;319(7201):23-4
references.pmid: 10390454
references.citation: Blood. 2005 Oct 15;106(8):2790-7
references.pmid: 15976177
references.citation: Int J Cancer. 2002 Mar 1;98(1):155-8
references.pmid: 11857400
references.citation: Infect Agent Cancer. 2010 Aug 31;5:14
references.pmid: 20807396
references.citation: J Immunol Methods. 2010 Apr 30;356(1-2):39-46
references.pmid: 20211626
references.citation: J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):620-5
references.pmid: 16044017
references.citation: AIDS. 2003 Jun 13;17(9):1394-6
references.pmid: 12799563
references.citation: AIDS. 2007 Aug 20;21(13):1717-21
references.pmid: 17690569
references.citation: J Infect Dis. 1999 Sep;180(3):600-6
references.pmid: 10438345
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):254-9
references.pmid: 9803967
references.citation: N Engl J Med. 1998 Apr 2;338(14):948-54
references.pmid: 9521982
references.citation: AIDS. 2004 Feb 20;18(3):485-93
references.pmid: 15090801
references.citation: Curr Opin HIV AIDS. 2006 Jan;1(1):43-9
references.pmid: 19372783
references.citation: AIDS. 2004 Jan 2;18(1):51-8
references.pmid: 15090829
references.citation: AIDS. 2008 May 31;22(9):1019-28
references.pmid: 18520345
references.citation: AIDS. 1998 Sep 10;12(13):1639-43
references.pmid: 9764783
references.citation: AIDS Res Hum Retroviruses. 2009 Jan;25(1):1-8
references.pmid: 19182916
references.citation: N Engl J Med. 1999 Jun 17;340(24):1863-71
references.pmid: 10369849